Table 1 Baseline characteristics of 298 patients who received either BNT162b2 or mRNA-1273
Characteristic | Value |
|---|---|
Median Age, yrs (range) | 61 yrs (21–79) |
Gender, n (%) | |
 Male | 169 (56.7) |
 Female | 129 (40.3) |
Vaccine Received, n (%) | |
 BNT162b2 | 188 (63.1) |
 mRNA-1273 | 110 (36.9) |
Booster Received, n (%) | 54 (18.1) |
Median time to Booster, days (range) | 186 days (53–266) |
Primary diagnosis at HCT, n (%) | |
 AML | 118 (39.6) |
 ALL | 54 (18.1) |
 Myelodysplastic syndromes/ myeloproliferative neoplasms | 38 (12.8) |
 Myelofibrosis | 30 (10.1) |
 Other | 58 (19.5) |
HCT Donor, n (%) | |
 MRD | 83 (27.9) |
 MUD | 147 (49.3) |
 MMUD | 16 (5.4) |
 HAPLO | 48 (16.1) |
 MMRD | 1 (0.3) |
 CORD | 3 (1.0) |
Median day after HCT, days (range) | 628.5 days (71–11,199) |
GvHD Prior to Vaccine, n (%) | 119 (39.9) |
Location of GvHD, n (%) | |
 Skin/Joints | 74 (24.8) |
 Eyes | 37 (12.4) |
 Mouth | 45 (15.1) |
 GI | 16 (5.4) |
 Liver | 22 (7.4) |
Immunosuppressants, n (%) | 187 (62.8) |
 Corticosteroids | 52 (17.4) |
 Tacro | 126 (42.3) |
 Siro | 86 (28.9) |
 MMF | 13 (4.4) |
 Jakafi | 46 (15.4) |
 Other systemic agents | 8 (2.7) |